Carlos O Stalgis from 29877 Westhaven Dr, Calabasas, CA 91301, age 66, Phone: 9084004283

Ribavirin-Pegylated Interferon Alfa Induction Hcv Combination Therapy
view source
US Patent:

20020119122, Aug 29, 2002
Filed:

Dec 16, 1999
Appl. No.:

09/464426
Inventors:

CARLOS O. STALGIS - MILLINGTON NJ, US
JANICE K. ALBRECHT - WINTER PARK FL, US
PAUL W. GLUE - FLEMINGTON NJ, US
International Classification:

A61K038/21
A61K039/12
US Classification:

424/085700, 424/204100
Abstract:

There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g. , pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.

Hiv Therapy
view source
US Patent:

20020182179, Dec 5, 2002
Filed:

Mar 1, 2000
Appl. No.:

09/516673
Inventors:

Mark Laughlin - Edison NJ, US
Paul Glue - Flemington NJ, US
Carlos Stalgis - Millington NJ, US
International Classification:

A61K038/21
US Classification:

424/085700
Abstract:

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b as monotherapy or preferably in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.

Carlos O Stalgis